Uniquity Bio Appoints Jason Moore as SVP of Regulatory & Quality Ahead of Pivotal Solrikitug Data Readouts
核心洞察
Uniquity Bio (搜索) has appointed Jason Moore as Senior Vice President of Regulatory & Quality as the company prepares for potential late-stage development of its lead asset, solrikitug.
Topline data from Phase II trials of solrikitug in asthma (搜索), COPD, and eosinophilic esophagitis (搜索) are expected later this year.
Moore brings extensive regulatory experience, including leading the clinical development and marketing applications for AIRSUPRA in partnership with AstraZeneca.
Uniquity Bio (搜索), a clinical-stage drug development company focused on immunology and inflammation and backed by Blackstone Life Sciences (搜索), announced the appointment of Jason Moore as Senior Vice President, Regulatory & Quality. The strategic hire comes as the company readies for the potential late-stage development of its lead asset, solrikitug, with topline data readouts expected this year from its Phase II trials in asthma (搜索), chronic obstructive pulmonary disease (搜索) (COPD), and eosinophilic esophagitis (搜索) (EoE).
"Adding Jason to our leadership team strengthens our position to move efficiently into late-stage development if the data supports it," said Will Kane, President and CEO of Uniquity Bio (搜索). "He brings an extensive track record of strategic diligence and regulatory judgment, fueled by a deep commitment to the safety and experience of the patients we aim to serve. We're fortunate to have him with us as Uniquity continues to evolve."
Moore's Regulatory Track Record
Moore most recently served as the Senior Vice President of Regulatory Affairs & Quality Assurance at Nefro Avillion Clinical Development. Prior to that, he held an executive role at Avillion Life Sciences — acquired by Nefro Health in 2025 — where he oversaw the clinical development and marketing applications of AIRSUPRA to successful completion in partnership with AstraZeneca, among other initiatives.
His career also includes serving as a principal consultant with JEM Biopharma Consulting and holding senior roles in regulatory, quality, clinical, and program management with Camargo Pharmaceutical Services, PLx Pharma, and BioHouston. Throughout his career, Moore has consistently led strategies for product development, risk management, Health Authority engagement, and global regulatory requirements, and has provided strategic diligence for licensing, portfolio strategy, and M&A decisions. He has served on more than 15 advisory boards and holds an M.S. from Texas A&M University and an MBA from the University of Houston.
"I've been impressed by the rigor that Uniquity's team brings to all aspects of development, and I'm eager to contribute to that work as we move into a new stage," said Moore. "I look forward to building on the company's strong regulatory and quality foundation to ensure excellence as we scale."
Solrikitug: A TSLP (搜索)-Targeting Monoclonal Antibody
Solrikitug is a highly potent monoclonal antibody targeting thymic stromal lymphopoietin (TSLP (搜索)), an immune signaling protein implicated in multiple inflammatory diseases. The therapy was in-licensed from Merck & Co. (搜索), Inc. (known as MSD outside of the U.S. and Canada) and is being evaluated across several respiratory and gastrointestinal indications with significant unmet medical needs.
In addition to finalizing Phase II trials for solrikitug and preparing for late-stage development, Uniquity is in the process of identifying bispecific and/or combination product candidates for clinical testing. By combining solrikitug with other key inflammatory targets, the company could potentially enhance efficacy and broaden the applicable patient population in specific indications.
The appointment underscores Uniquity's preparations for a potential transition into late-stage clinical development, a phase that requires increased regulatory oversight, manufacturing quality controls, and extensive engagement with global health authorities. Strengthening regulatory leadership ahead of key clinical data is a common step for biotechnology companies positioning lead drug candidates for pivotal trials and potential commercialization.